-
Company Insights
NewDeere & Company – Digital Transformation Strategies
Deere & Company Digital Transformation Strategies Report Overview Deere & Company (John Deere) has been focusing on using artificial intelligence, the Internet of Things (IoT), cloud-based mobile applications, big data, and drones to digitally transform its operations. The annual ICT spending of John Deere was estimated at $3.6 billion for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. John Deere is a provider of advanced products and services. It manufactures...
-
Track & Monitor
NewArtificial intelligence in oil & gas: oil exploration AI
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the oil & gas industry’s oil exploration AI segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
NewNet Present Value Model: Johnson & Johnson’s Gemcitabine
Empower your strategies with our Net Present Value Model: Johnson & Johnson's Gemcitabine report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Johnson & Johnson’s Nipocalimab
Empower your strategies with our Net Present Value Model: Johnson & Johnson's Nipocalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Quavonlimab
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Quavonlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Vibostolimab
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Vibostolimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Nemtabrutinib
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Nemtabrutinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Clesrovimab
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Clesrovimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Favezelimab
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Favezelimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Sotatercept
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Sotatercept report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.